|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-12-12
|
|
pubmed:abstractText |
Although long-term use of morphine has been shown to promote tumor growth, the question whether tumorigenesis occurs as a result of an immunosuppressive effect remains to be investigated. In mice rendered tolerant to morphine, the efficacy and mechanism of a vaccination to rescue morphine-induced immunosuppression and prevent tumor growth was assessed both in vitro and in vivo. Herein, we found that morphine-injected mice exhibited higher tumor growth rates and lower percentages of CD8+ T lymphocytes. The mechanism of morphine suppression of immunity might be through the suppression of E7-specific CD8+ T lymphocyte proliferation and the promotion of apoptosis of these cells by the Bcl-2 and Bax pathways. The suppressive effect of E7-specific CD8+ T lymphocytes by morphine could be reversed by naloxone. We have previously shown that calreticulin linked with E7 (CRT/E7) could enhance the CD8+ T cell response and the anti-tumor effects (W. F. Cheng et al. (2001) J. Clin. Invest. 108, 669-678). CRT/E7 DNA vaccine could overcome the immunosuppressive effect of morphine and suppress tumor growth. Our findings reveal that long-term morphine treatment dose-dependently promotes tumor growth and a DNA vaccine may serve as a useful approach to treat the profound immunosuppressive function and prevent tumorigenesis after long-term morphine treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1525-0016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
203-10
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16140583-Analgesics, Opioid,
pubmed-meshheading:16140583-Animals,
pubmed-meshheading:16140583-Apoptosis,
pubmed-meshheading:16140583-CD4-Positive T-Lymphocytes,
pubmed-meshheading:16140583-CD8-Positive T-Lymphocytes,
pubmed-meshheading:16140583-Cancer Vaccines,
pubmed-meshheading:16140583-Cell Line, Tumor,
pubmed-meshheading:16140583-Female,
pubmed-meshheading:16140583-Immunosuppression,
pubmed-meshheading:16140583-Mice,
pubmed-meshheading:16140583-Mice, Inbred C57BL,
pubmed-meshheading:16140583-Morphine,
pubmed-meshheading:16140583-Narcotic Antagonists,
pubmed-meshheading:16140583-Neoplasm Transplantation,
pubmed-meshheading:16140583-Neoplasms, Experimental,
pubmed-meshheading:16140583-Papillomavirus E7 Proteins,
pubmed-meshheading:16140583-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:16140583-Transplantation, Heterologous,
pubmed-meshheading:16140583-Vaccination,
pubmed-meshheading:16140583-Vaccines, DNA,
pubmed-meshheading:16140583-bcl-2-Associated X Protein
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Chimeric DNA vaccine reverses morphine-induced immunosuppression and tumorigenesis.
|
|
pubmed:affiliation |
Obstetrics and Gynecology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
